# A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

> **NCT01469000** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 195 (actual)

## Conditions studied

- Carcinoma, Non Small Cell Lung

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT01469000
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2015-04
- **Final completion:** 2017-11
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01469000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01469000, "A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01469000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*